SLXN FY2026 EPS Increased by Litchfield Hills Research

Silexion Therapeutics Corp (NASDAQ:SLXN) – Stock analysts at Litchfield Hills Research raised their FY2026 EPS estimates for Silexion Therapeutics in a research report issued on Monday, September 21st. Litchfield Hills Research analyst T. O’neill now forecasts that the company will post earnings per share of ($4.70) for the year, up from their previous estimate of ($45.50). The consensus estimate for Silexion Therapeutics’ current full-year earnings is ($45.50) per share.

A number of other research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Silexion Therapeutics presently has an average rating of “Hold”.

Silexion Therapeutics Trading Down 27.9%

Shares of NASDAQ SLXN opened at $0.39 on Wednesday. The stock has a 50-day moving average price of $1.08 and a two-hundred day moving average price of $5.36. Silexion Therapeutics has a 12 month low of $0.32 and a 12 month high of $42.60. The company has a market cap of $2.18 million, a price-to-earnings ratio of -0.01 and a beta of -0.36.

Silexion Therapeutics (NASDAQ:SLXN) last announced its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.